Ozenoxacin (Dubine®)

Assessment Status Rapid Review Complete
Drug Ozenoxacin
Brand Dubine®
Indication For the short term treatment of non-bullous impetigo in adults, adolescents, children, and infants aged 6 months and older.
Assessment Process
Rapid review commissioned 12/11/2018
Rapid review completed 13/12/2018
Rapid review outcome A full HTA is not recommended. The NCPE recommends that ozenoxacin cream not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.